Connect with us
PharmaMar's shares surged 32.7% after announcing positive phase III trial results for Zepzelca, combined with Tecentriq, in treating advanced small cell lung cancer. This combination significantly...
Grifols achieved its best score in the S&P Global Sustainability ranking with 70 points, improving by seven from last year. The ranking recognized its advancements in...
Peaches Biotech is investing €6.8 million in a new secretome platform study, with phases I and II ending this year and the final phase starting in...
AI-powered ultrasound software enhances real-time guidance, ensuring optimal images and reducing errors, enabling more accurate diagnoses without complex machines. Dr. Ana Segura highlighted its transformative impact...
A meeting organized by Sedisa and the ECO Foundation highlighted the need for efficient management of oncological resources to ensure equity in access to treatments. Attendees,...
Substrate AI acquired 4D Médica in 2022 for €1.4 million to boost its health sector, aiming to quadruple revenues to €2.8 million by 2023. The deal,...
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...
Alfasigma has acquired the marketing rights for Jyseleca, a JAK1 inhibitor drug used for rheumatoid arthritis and ulcerative colitis, following European Medicines Agency approval. This acquisition...
Oryzon Genomics shares rose 2.8% after receiving positive FDA feedback on vafidemstat for borderline personality disorder. The company plans a Phase III study with 350 patients...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....
 |
|
 |  |
 |
|